Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BTK C481F |
Therapy | Acalabrutinib |
Indication/Tumor Type | hematologic cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK C481F | hematologic cancer | resistant | Acalabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BTK C481F were resistant to treatment with Calquence (acalabrutinib) in culture (PMID: 35639855). | 35639855 |
PubMed Id | Reference Title | Details |
---|---|---|
(35639855) | Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. | Full reference... |